Diego de Castro dos Santos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Diego de Castro dos Santos has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Fernando Freua
Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Departamento de Neurologia, São Paulo SP, Brazil
2 shared publications Fernando Kok
Department of Neurology, Neurogenetics Center University of São Paulo São Paulo Brazil
2 shared publications- Leandro Tavares Lucato
Neuroradiology Section, Hospital das Clinicas (HCFMUSP) Faculdade de Medicina, Universidade de São Paulo Sao Paulo Brazil
2 shared publications - Alex Tiburtino Meira
Department of Internal Medicine, Federal University of Paraiba, Joao Pessoa, Brazil
1 shared publication - Anderson Rodrigues Brandão de Paiva
Neurogenetics Unit, Department of Neurology University of Sao Paulo School of Medicine Sao Paulo Brazil
1 shared publication - Andre Luiz Santos Pessoa
Hospital Infantil Albert Sabin, Fortaleza, Brazil
1 shared publication
Latest Publications
- 7 July 2026
- Published by Wiley in Movement Disorders Clinical Practice
Novel Homozygous Pathogenic Variant in DNAJC6 Causes Rapid Progressive Parkinsonism
Background: Biallelic variants in DNAJC6 cause PARK‐ DNAJC6 (historically referred to as PARK19), a rare autosomal recessive juvenile‐onset dystonia‐parkinsonism syndrome. Neurodevelopmental delay or regression, epilepsy, movement disorders, and psychiatric symptoms are also present. Progression is fast with frequent bulbar, gastrointestinal involvement and early loss of ambulation. Cases: We report two siblings (17 and 14 years) harboring a novel homozygous nonsense variant in DNAJC6 , p.Cys325*, not previously described in the medical literature and absent from population databases. The variant is predicted to truncate the protein, supporting a loss‐of‐function mechanism consistent with the gene's disease biology. Both patients exhibited developmental regression, parkinsonism with dystonia, cognitive decline, dysphagia, and marked sialorrhea, with severe, accelerated functional deterioration. Levodopa produced only mild benefit; in the older sibling, dose escalation provoked an adverse reaction with sustained upgaze/ophthalmoparesis, opisthotonus, and hypertension. Literature review: We found 23 previously reported DNAJC6 patients, most with early‐onset parkinsonism with variable levodopa responsiveness, frequent developmental and psychiatric comorbidity, and prominent bulbar features. Conclusions: The novel DNAJC6 p.Cys325* variant is associated with severe, early‐onset parkinsonism and developmental regression. DNAJC6 should be considered in children and adolescents presenting with parkinsonism plus neurodevelopmental decline, particularly when levodopa benefit is modest, and dose‐related adverse motor crises occur.
- 7 July 2026
- Published by Wiley in Movement Disorders Clinical Practice
Novel Homozygous Pathogenic Variant in DNAJC6 Causes Rapid Progressive Parkinsonism
Background: Biallelic variants in DNAJC6 cause PARK‐ DNAJC6 (historically referred to as PARK19), a rare autosomal recessive juvenile‐onset dystonia‐parkinsonism syndrome. Neurodevelopmental delay or regression, epilepsy, movement disorders, and psychiatric symptoms are also present. Progression is fast with frequent bulbar, gastrointestinal involvement and early loss of ambulation. Cases: We report two siblings (17 and 14 years) harboring a novel homozygous nonsense variant in DNAJC6 , p.Cys325*, not previously described in the medical literature and absent from population databases. The variant is predicted to truncate the protein, supporting a loss‐of‐function mechanism consistent with the gene's disease biology. Both patients exhibited developmental regression, parkinsonism with dystonia, cognitive decline, dysphagia, and marked sialorrhea, with severe, accelerated functional deterioration. Levodopa produced only mild benefit; in the older sibling, dose escalation provoked an adverse reaction with sustained upgaze/ophthalmoparesis, opisthotonus, and hypertension. Literature review: We found 23 previously reported DNAJC6 patients, most with early‐onset parkinsonism with variable levodopa responsiveness, frequent developmental and psychiatric comorbidity, and prominent bulbar features. Conclusions: The novel DNAJC6 p.Cys325* variant is associated with severe, early‐onset parkinsonism and developmental regression. DNAJC6 should be considered in children and adolescents presenting with parkinsonism plus neurodevelopmental decline, particularly when levodopa benefit is modest, and dose‐related adverse motor crises occur.
- 10 April 2026
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (9) , 2311-2313
Drinking‐Induced Orolingual Tremor: Report of Two Cases with a Novel Response to Propranolol
- 10 April 2026
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (9) , 2311-2313
Drinking‐Induced Orolingual Tremor: Report of Two Cases with a Novel Response to Propranolol
- 5 January 2024
- Published by Wiley in Movement Disorders
- Vol. 39 (2) , 227-234
The Huntington's Disease Gene Discovery
The gene for Huntington's disease (HD) was discovered in 1993, after an international collaborative initiative that led researchers to remote regions of South America. It was the most remarkable milestone, since George Huntington's initial description. Through the phenomenological discussions led by Jean‐Martin Charcot and Willian Osler, and finally Americo Negrette's reports, which served as the inspiration for the Venezuela Project led by Nancy Wexler, the journey toward discovering the Huntington's disease (HD) gene was marked by substantial efforts. This monumental achievement involved the analysis of more than 18,000 blood samples and gathered dozens of researchers in an integrated effort, enabling the mapping of the gene on chromosome 4 in 1983 and leading, a decade later, to the precise localization and identification of the HTT gene. The discovery of the HD mutation represented a pivotal moment in the field of genetics and neurology, significantly enhancing our understanding of the disease and creating opportunities for future treatments. The progress made and the knowledge gained during this journey catalyzed the development of many innovative molecular techniques that have advanced research in other medical conditions. In this article, the authors celebrate three decades of this memorable event, revisiting the historical aspects, providing insights into the techniques developed, and delving into the paths that ultimately led to the discovery of the HD gene. © 2024 International Parkinson and Movement Disorder Society.
- 5 January 2024
- Published by Wiley in Movement Disorders
- Vol. 39 (2) , 227-234
The Huntington's Disease Gene Discovery
The gene for Huntington's disease (HD) was discovered in 1993, after an international collaborative initiative that led researchers to remote regions of South America. It was the most remarkable milestone, since George Huntington's initial description. Through the phenomenological discussions led by Jean‐Martin Charcot and Willian Osler, and finally Americo Negrette's reports, which served as the inspiration for the Venezuela Project led by Nancy Wexler, the journey toward discovering the Huntington's disease (HD) gene was marked by substantial efforts. This monumental achievement involved the analysis of more than 18,000 blood samples and gathered dozens of researchers in an integrated effort, enabling the mapping of the gene on chromosome 4 in 1983 and leading, a decade later, to the precise localization and identification of the HTT gene. The discovery of the HD mutation represented a pivotal moment in the field of genetics and neurology, significantly enhancing our understanding of the disease and creating opportunities for future treatments. The progress made and the knowledge gained during this journey catalyzed the development of many innovative molecular techniques that have advanced research in other medical conditions. In this article, the authors celebrate three decades of this memorable event, revisiting the historical aspects, providing insights into the techniques developed, and delving into the paths that ultimately led to the discovery of the HD gene. © 2024 International Parkinson and Movement Disorder Society.
- Open Access
- 5 August 2023
- Published by MDPI AG in Brain Sciences
- Vol. 13 (8) , 1169
Subacute Partially Reversible Leukoencephalopathy Expands the Aicardi–Goutières Syndrome Phenotype
Objective: To report a series of atypical presentations of Aicardi–Goutières syndrome. Methods: Clinical, neuroimaging, and genetic data. Results: We report a series of six unrelated patients (five males) with a subacute loss of developmental milestones, pyramidal signs, and regression of communication abilities, with onset at ages ranging from 7 to 20 months, reaching a nadir after 4 to 24 weeks. A remarkable improvement of lost abilities occurred in the follow-up, and they remained with residual spasticity and dysarthria but preserved cognitive function. Immunization or febrile illness occurred before disease onset in all patients. CSF was normal in two patients, and in four, borderline or mild lymphocytosis was present. A brain CT scan disclosed a subtle basal ganglia calcification in one of six patients. Brain MRI showed asymmetric signal abnormalities of white matter with centrum semi-ovale involvement in five patients and a diffuse white matter abnormality with contrast enhancement in one. Four patients were diagnosed and treated for acute demyelinating encephalomyelitis (ADEM). Brain imaging was markedly improved with one year or more of follow-up (average of 7 years), but patients remained with residual spasticity and dysarthria without cognitive impairment. Demyelination relapse occurred in a single patient four years after the first event. Whole-exome sequencing (WES) was performed in all patients: four of them disclosed biallelic pathogenic variants in RNASEH2B (three homozygous p.Ala177Thr and one compound heterozygous p.Ala177Thr/p.Gln58*) and in two of them the same homozygous deleterious variants in RNASEH2A (p.Ala249Val). Conclusions: This report expands the phenotype of AGS to include subacute developmental regression with partial clinical and neuroimaging improvement. Those clinical features might be misdiagnosed as ADEM.
- 5 August 2023
- Published by MDPI AG in Brain Sciences
- Vol. 13 (8) , 1169
Open AccessSubacute Partially Reversible Leukoencephalopathy Expands the Aicardi–Goutières Syndrome Phenotype
Objective: To report a series of atypical presentations of Aicardi–Goutières syndrome. Methods: Clinical, neuroimaging, and genetic data. Results: We report a series of six unrelated patients (five males) with a subacute loss of developmental milestones, pyramidal signs, and regression of communication abilities, with onset at ages ranging from 7 to 20 months, reaching a nadir after 4 to 24 weeks. A remarkable improvement of lost abilities occurred in the follow-up, and they remained with residual spasticity and dysarthria but preserved cognitive function. Immunization or febrile illness occurred before disease onset in all patients. CSF was normal in two patients, and in four, borderline or mild lymphocytosis was present. A brain CT scan disclosed a subtle basal ganglia calcification in one of six patients. Brain MRI showed asymmetric signal abnormalities of white matter with centrum semi-ovale involvement in five patients and a diffuse white matter abnormality with contrast enhancement in one. Four patients were diagnosed and treated for acute demyelinating encephalomyelitis (ADEM). Brain imaging was markedly improved with one year or more of follow-up (average of 7 years), but patients remained with residual spasticity and dysarthria without cognitive impairment. Demyelination relapse occurred in a single patient four years after the first event. Whole-exome sequencing (WES) was performed in all patients: four of them disclosed biallelic pathogenic variants in RNASEH2B (three homozygous p.Ala177Thr and one compound heterozygous p.Ala177Thr/p.Gln58*) and in two of them the same homozygous deleterious variants in RNASEH2A (p.Ala249Val). Conclusions: This report expands the phenotype of AGS to include subacute developmental regression with partial clinical and neuroimaging improvement. Those clinical features might be misdiagnosed as ADEM.
- Open Access
- 1 February 2019
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 5 (1) , e306
PUS3 mutations are associated with intellectual disability, leukoencephalopathy, and nephropathy
- 1 February 2019
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 5 (1) , e306
Open AccessPUS3 mutations are associated with intellectual disability, leukoencephalopathy, and nephropathy
- 1 July 2018
- Published by American Medical Association (AMA) in JAMA Neurology
- Vol. 75 (7) , 896
Association of Optic Pathways and Brain Structure With Deep Brain Stimulation of the Nucleus Basalis of Meynert for Parkinson Disease Dementia
To the Editor We read with interest the article by Gratwicke et al1 that described deep brain stimulation of the nucleus basalis of Meynert (NBM DBS) and the potential symptomatic effects in patients with Parkinson disease dementia. No consistent improvements were observed in the primary cognitive outcomes. However, the authors found evidence of improvements in neuropsychiatric symptoms, probably driven by a reduction in complex visual hallucinations. Although modest, these findings encourage further DBS research in this subgroup of patients.
- 1 July 2018
- Published by American Medical Association (AMA) in JAMA Neurology
- Vol. 75 (7) , 896
Association of Optic Pathways and Brain Structure With Deep Brain Stimulation of the Nucleus Basalis of Meynert for Parkinson Disease Dementia
To the Editor We read with interest the article by Gratwicke et al1 that described deep brain stimulation of the nucleus basalis of Meynert (NBM DBS) and the potential symptomatic effects in patients with Parkinson disease dementia. No consistent improvements were observed in the primary cognitive outcomes. However, the authors found evidence of improvements in neuropsychiatric symptoms, probably driven by a reduction in complex visual hallucinations. Although modest, these findings encourage further DBS research in this subgroup of patients.